#1For personal use only. INOVIQ Investor Presentation Bell Potter Healthcare Conference 2023 ASX: IIQ | 16 November 2023#2Disclaimer Cat This presentation has been prepared by INOVIQ Limited ("INOVIQ" or the "Company") based on information available to it as at the date of this presentation. This presentation contains general and background information about the Company's activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision and does not contain all information about the Company's assets and liabilities, financial position and performance, profits and losses, prospects, and the rights and liabilities attaching to the Company's securities necessary to make an investment decision. The information in this presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), available at www.asx.com.au. The information in this presentation is based on the Company's own information and estimates and has not been independently verified. The Company is not responsible for Providing updated information and assumes no responsibility to do so. Any investment in the Company should be considered speculative and there is no guarantee that they will make a return on capital invested, that dividends would be paid, or that there will be an increase in the value of the investment in the future. This Presentation may contain certain "forward-looking statements" that are based on management's beliefs, assumptions and expectations and on information currently available to management. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings, financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward- looking statement by any person (including INOVIQ or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur. Actual operations, results, performance, targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Nothing contained in this Presentation constitutes investment, legal, tax or other advice. This Presentation does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects. You should note that any past performance is given for illustrative purposes only and should not be relied on as (and is not) an indication of the Company's views on its future financial performance or condition. Past performance, including past share price performance, of INOVIQ cannot be relied on as an indicator of (and provides no guidance as to) future performance including future share price performance. 2 INOVIQ#3Company snapshot Precision focus Precision diagnostic and exosome solutions to improve personal use only patient outcomes Compelling data $ Financial information (ASX:IIQ) Ordinary shares² 92,018,702 Disruptive technology Deep pipeline Proprietary technology platforms driving future products for cancer and other diseases Commercial products Multi-stage pipeline including SubB2M diagnostics, exosome research tools and exosome diagnostics Partnering for growth Listed options² 52-week H/L² Share price² 2,611,349 A$0.990-0.460 A$0.60 Market capitalisation² A$55.2m Cash at bank¹ A$6.3m Major shareholders (as at 10 November 2023) Merchant Funds Mgt Pty Ltd 14.2% Moggs Creek/Lawn Views Pty Ltd 5.3% Share price performance $1.00 $0.90 High accuracy exosome isolation tools and diagnostics for breast and ovarian cancers Commercial exosome isolation tools and bladder cancer detection test Partnering with KOLs and Industry to deliver clinical and commercial outcomes 1. Cash at 30 Sep 2023 (ASX: 30 Oct 2023); 2. As at 10 Nov 2023 $0.80 $0.70 $0.60 $0.50 $0.40 Jun Jul Aug Sep Oct 0 Nov INOVIQ 3M 2M 1M#4Board and Management | Healthcare, corporate & commercial experience For personal use only 4 DR GEOFF CUMMING Non-Executive Chairman Healthcare and biotechnology director with extensive diagnostics industry experience. Previously Managing Director Roche Diagnostic Systems (Oceania), MD/CEO Biosceptre International Ltd and MD/CEO of Anteo Diagnostics Ltd. Currently NED AnteoTech Ltd. MAX JOHNSTON Non-Executive Director Healthcare industry director and international business leader with extensive experience across medtech, pharmaceuticals, consumer healthcare and consumer goods. Previously President and CEO of Johnson & Johnson Pacific, Chairman of AusCann Ltd, NED of PolyNovo Ltd, Medical Developments International Ltd, Tissue Repair Ltd and CannPal Animal Therapeutics Ltd. PHILIP POWELL Non-Executive Director Healthcare industry director and chartered accountant with extensive investment banking experience specialising in capital raisings, IPOs, mergers and acquisitions and other transactions across pharma, food and agriculture. Previously at OAMPS Ltd and Arthur Andersen, and NED at Polynovo Ltd and Medical Developments International Ltd. Currently NED RMA Global Ltd. DR LEEARNE HINCH Chief Executive Officer Biotechnology CEO with a successful track record in corporate development, capital raising, product development, commercialisation and licensing. Past leadership and consulting roles in ASX- listed biotechnology, multinational and private companies across diagnostics, devices, therapeutics and animal health including Eustralis Pharmaceuticals, HealthLinx, OBJ, Holista Colltech, Virbac and Mars. DR GREG RICE Chief Scientific Officer Internationally recognized, award winning scientist with over 35 years' experience and a successful track record in oncology research, exosome science, biomarker discovery, and diagnostics development. Previous leadership roles in academia and industry including at Uni Queensland Centre for Clinical Research, Baker Heart Institute, University of Melbourne, Monash University and Health Linx. MARK EDWARDS CFO & Company Secretary Highly experienced finance executive with expertise in financial leadership and management, corporate governance, investor relations and corporate transactions. Previous senior roles in ASX listed pharmaceutical, medical device and healthcare companies, including Medical Developments International and Cogstate. INOVIQ#5INOVIQ CY23 achievements Focuse on advancing the development and commercialisation of our SubB2M and EXO-NET platforms For personal use only Clinically validated SubB2M technology and commenced BC monitoring study to enable partnering for LDT commercialisation Developed, validated and commissioned high-throughput EXO-NET exosome isolation system to enable a complete exosome concept-to-clinic diagnostics solution Secured commercial partners for EXO-NET with Promega and ResearchDx to drive future revenues Progressed pipeline of EXO-NET research tools, SubB2M tests and exosome diagnostics Initiated discussions for potential co-development of exosome diagnostics (using EXO-NET) Expanded Board with the appointment of experienced director, David Williams, as Chairman elect¹ Excellent clinical ⚫data for SubB2M/CA15-3 breast cancer test announced INOVIQ INOVIQ announces global joint marketing agreement with Promega Promega INOVIQ & ResearchDX Sign a license and supply agreement for the provision of EXO-NET enabled diagnostic services in the USA INOVIQ INOVIQ EXO-NET 5 1. Subject to shareholder approval at upcoming INOVIQ AGM on 29 Nov 23 INOVIQ#63 business pillars | Research tools, diagnostics and therapeutics For personal use only 6 STRATEGIC FOCUS Leading exosome solutions and precision diagnostics company focused on improving patient outcomes for cancer EXO-NET immunoaffinity magnetic bead-based exosome isolation DISRUPTIVE TECHNOLOGY SubB2M technology for enhanced cancer detection EXO-ACE ion exchange chromatography for therapeutic exosome production RESEARCH TOOLS DIAGNOSTICS & SERVICES EXO-NET products SubB2M diagnostics Exosome diagnostics EXO-NET services hTERT test THERAPEUTICS Exosome therapeutics INOVIQ#7Products and pipeline | multi-stage research tools and cancer diagnostics Exosome research tools for exosome isolation, biomarker discovery and diagnostics development Blood tests for earlier and more accurate detection of breast, ovarian and other cancers PRODUCT hTERT¹ SubB2M-BC EXO topis/Dx Expersonal use only SubB2M-OC SubB2M-SPR EXO-OC² EXO-NET RUO TEXO-NET RUO INDICATION USE RESEARCH ASSAY CLINICAL MARKET DEVELOPMENT DEVELOPMENT Bladder Cancer Adjunct to cytology IVD-Class 1 USA Breast Cancer Monitoring LDT Ovarian Cancer Monitoring LDT Multi-cancer Pre-screening LDT Ovarian Cancer Screening LDT pan-EV capture Research tool RUO tumour derived-EV capture Research tool RUO brain derived-EV capture Research tool RUO NEURO-NET RUO NOTE: Development pipeline is indicative only, subject to review. 7 *EV = Extracellular Vesicles; ICC = Immunocytochemistry; IVD = In Vitro Diagnostic; LDT = Laboratory-Developed Test; RUO = Research Use Only 1. Adjunct to urine cytology to assist the detection of bladder cancer; 2 Umbrella Research & Option Agreement with the University of Queensland INOVIQ#8SubB2M technology platform Scientific rationale O Cancer cells have a distinct feature of adding different sugar Smolecules to the proteins they produce, which sets them apart ☐ from normal cells For personal use only Neu5Gc is a sugar molecule commonly found in cancer cells SubB2M is an engineered protein that preferentially binds to Neu5Gc SubB2M is a promising multicancer probe Incorporating SubB2M into existing cancer biomarker tests, may improve sensitivity and specificity for detecting various types of cancer Normal cells Expressing Neu5Ac glycoproteins 8 Neu5Gc = the sialic acid, N-glycolylneuraminic acid Changes in protein glycosylation Cellular transformation and progression Malignant cells Expressing Neu5Gc glycoproteins neu5Gc neu5Ac INOVIQ#9SubB2M/CA15-3 test | Breast Cancer monitoring Clinical-stage and progressing towards partner-ready by Dec 2023 to enable LDT commercialisation • #1 cancer in women For personal use only 9 Breast cancer • 2.3m new cases of breast cancer worldwide pa¹ • 7.8m survivors (5-year) 1 • Earlier and more accurate detection and monitoring tests required for breast cancer Development stage Completed Feasibility Unmet medical need Disruptive technology Intended use • US$4.2b global diagnostics market² • SubB2M is an engineered protein that specifically binds the pan-cancer biomarker Neu5Gc³ • Improved immunoassay for detection of Neu5Gc decorated CA15-3 • Increased sensitivity and specificity to detect cancer over existing assays • Aid in monitoring breast cancer treatment response and disease recurrence in women previously diagnosed with disease Assay development Completed Analytical validation (n=94) Completed Completed Clinical validation (n=483) Monitoring study H2 CY23 Go-to-market strategy •⚫LDT then IVD (510k/PMA process) • Partner with a CLIA-accredited laboratory 510k = FDA clearance for Class II device; CLIA = Clinical Laboratory Improvement Amendments (high-complexity tests); IVD = In Vitro Diagnostic; LDT = Laboratory Developed Test; 1. https://gco.iarc.fr/today/home; 2. https://www.grandviewresearch.com/industry-analysis/breast-cancer-diagnostics-market; 3 Neu5Gv = the sialic acid, N-glycolylneuraminic acid LDT partner ready Dec 2023 INOVIQ#10SubB2M/CA15-3 Test: data and plans Clinical validation study | completed Retrospective, case-control, clinical validation study in 483-samples demonstrated SubB2M/CA15-3 test detected breast cancer across Sall stages with high accuracy (AUC 0.93, 81% sensitivity and 93% ☐ specificity) and outperformed a leading approved CA15-3 test¹ biomarker concentration For personal use only Breast Cancer monitoring study | commenced 2-phase monitoring study in over 200-samples to evaluate performance of SubB2M/CA15-3 test as an aid for monitoring treatment response and/or disease recurrence compared to approved CA15-3 test Data expected Dec-23 SubB2M/CA15-3 and comparator CA15-3 test performance summary Breast Cancer All Stages AUC sensitivity specificity SubB2M Comparator 0.93 0.70 81% 37% 93% 88% false negative rate 19% 63% false positive rate 7% 12% positive predictive value 92% 75% negative predictive value 83% 58% overall accuracy 87% 63% Test Sensitivity by stage @95% Specificity 100% 79% 80% 76% 72% 71% 64% 60% 40% 24% 23% 17% 18% 20% 18% primary treatment recurrence & treatment tumor growth treatment response treatment response 0% Stage I Stage II Stage III Comparator SubB2M Stage IV All Stages 10 1. SubB2M/CA15-3 clinical validation results (ASX: 27/6/23) Breast cancer (n=241: 1=75, II=72, 3=72, III=72, IV = 22) and healthy controls (n=242) INOVIQ#11Breast cancer monitoring study | Study 1 design For personal use only Study 1: To determine whether SubB2M/CA15-3 is equally expressing in women with different subtypes of breast cancer Pre-treatment serum Hormone receptor breast cancer (n=50) Her2 positive breast cancer (n=50) Triple Negative breast cancer (n=50) Age matched controls (n=65) SubB2M/CA15-3 test comparison between types of BC comparison between test IVD CA15-3 test 11 INOVIQ#12Breast cancer monitoring study | Study 2 design Study 2: To determine the accuracy of SubB2M/CA15-3 to identify breast cancer recurrence For personal use only pre-treatment post-treatment time 3 time 4 time 5 no recurrent disease (n=12) SubB2M/CA15-3 test comparison between recurrence and non- recurrence recurrent disease (n=12) IVD CA15-3 test comparison between test INOVIQ 12 12#13SubB2M/CA125 Test | Ovarian Cancer monitoring Progressing towards clinical validation For personal use only Ovarian cancer Unmet medical need Disruptive technology Intended use ⚫ #8 cancer in women & deadliest gynaecological cancer • 314k new cases of ovarian cancer worldwide pa¹ ⚫823k survivors (5-year)1 • Earlier and more accurate detection and monitoring tests required for ovarian cancer ⚫ US$1.8b global diagnostics market² • SubB2M is an engineered protein that specifically binds the pan-cancer biomarker Neu5Gc • Improved immunoassay for detection of Neu5Gc decorated CA125 • Increased sensitivity and specificity to detect cancer over existing assays • Aid in monitoring ovarian cancer treatment response and disease recurrence in women previously diagnosed with disease Go-to-market strategy •⚫LDT then IVD (510k/PMA process) • Partner with a CLIA-accredited laboratory Development stage Feasibility Completed Assay development H2 CY23 Analytical validation H2 CY23 Clinical validation H2 CY23 Monitoring study H1 CY24 LDT partner ready Jun 2024 13 1. Cancer Today (iarc.fr); 2. Ovarian Cancer Diagnostics Market Size Worth US$ 1.8 Bn by (globenewswire.com) INOVIQ#14SubB2M | Go-to-market strategy For personal use only 14 SubB2M/CA15-3 test is expected to be partner-ready in December 2023 for commercialisation as a Laboratory Developed Test Build analytical and clinical validation data package Commercialise first as an LDT in the USA with a lab partner to generate early revenue Complete IVD medical device development and regulatory approval via 510k / PMA pathway Secure IVD partners and approvals in major markets to expand geographic reach and grow revenue 510k = FDA clearance for Class II device; CLIA = Clinical Laboratory Improvement Amendments (high-complexity tests); CMS = Centers for Medicare and Medicaid Services; IVD = In Vitro Diagnostic; FDA = US Food & Drug Administration; LDT = Laboratory Developed Test; MDR = Medical Device Regulations; OC = Ovarian Cancer; PMA = FDA premarket approval for Class III device; KOL = Key Opinion Leader INOVIQ#15Market potential | Screening and monitoring tests For personal use only 15 Ovarian cancer - EU5 ■ US ■ AU Statistics¹ Eligible screening population² Eligible monitoring population³ Global Market size 4,5 Ovarian cancer incidence 52,638 Ovarian cancer prevalence 154,831 Breast cancer incidence 543,972 4.0 60.4 119m 54.7 11.5 188.3 $1.9b 367k 167.3 GLOBAL DX MARKET (Millions of people) (Thousands of people) (US$ billions) 4.0 Breast cancer 54.7 119m ■ EU5 - US Breast cancer prevalence 2,279,467 ■ AU (Millions of people) 60.4 2.1 0.2 4.46m (Millions of people) 2.2 $4.2b GLOBAL DX MARKET (US$ billions) 1 Source: https://gco.iarc.fr/today/home covering US, EU5 and AU; 2. Females 50-79yrs covering US, EU5 and AU (Source: https://www.populationpyramid.net ).; 3. Monitoring population based on 4x incidence plus 1x prevalence; 4. https://www.globenewswire.com/news-release/2019/08/07/1898453/0/en/Ovarian-Cancer-Diagnostics-Market-Size-Worth-US-1-8-Bn-by-2026.html 5. https://www.grandviewresearch.com/industry-analysis/breast-cancer-diagnostics-market INOVIQ#16For personal use only Exosomes | Diagnostic and therapeutic potential Image source: Meletios Verras/Shutterstock.com; 1. MarketandMarkets. Exosome Research Market (2021-2026). 2020; 2. Exosomes Market: Global Industry Analysis and Forecast (2023-2029) (maximizemarketresearch.com) • . Exosomes are released by cells and perform key roles in intercellular communication, immune regulation and pathogenesis Diseases elicit changes in the release of exosomes and their molecular cargo (DNA, RNA and proteins) Exosomes can be isolated from biofluids (including blood, urine and saliva) and their messages "read" to diagnose the health or disease status of the parent cell Exosome diagnostics and therapeutics are being developed for oncology, neurology, cardiology, immunology, inflammatory and other diseases Commercial potential limited by time-consuming and inefficient exosome isolation methods that are not suitable for commercial applications INOVIQ has developed fast, efficient and scalable exosome isolation technology US$661m Exosome research market¹ US$8.7b Exosome diagnostic & therapeutic market² INOVIQ#17EXO-NETⓇ | Exosome isolation tools For personal use only 17 Immunoaffinity magnetic bead-based capture system for isolation and analysis of exosomes Rapid, Simple, Cost-effective Scalable Full automation CGMP Compatible downstream analysis Enriches relevant EVs Reproducible Compatible with path lab workflow and platforms INOVIQ EXO-NET Pan-exosome capture Magnetic Particles 40031 -50eactions Store at 4°C Do not fe INOVIQ#18EXO-NET research tools and services | commercially available personal use only INOVIQ EXO-NET Pan-exosome capture Magnetic Particles 40031 Net Size 1 m 50 reactions Store at C Do not freeze EXO-NET PAN- EXOSOME CAPTURE EXO-NET is a research tool for fast, efficient & scalable exosome isolation from plasma, serum, urine, saliva and cell-conditioned media 1,2,3 CUSTOMISED EXO-NET TOOLS Design custom EXO-NET tools using ligands for specific EV populations (000) EXOSOME ISOLATION EV isolation using EXO-NET powered, fully-automated, high-throughput platform¹ BIOMARKER DISCOVERY Biomarker discovery to identify, evaluate and validate EV- based RNA and Protein biomarkers DIAGNOSTICS DEVELOPMENT EV-based clinical diagnostics, clinical trial assays ResearchDX and companion diagnostics INOVIQ 18 1. EXO-NET data at ISEV (ASX: 19/5/23); 2. Promega EXO-NET Co-marketing Agreement (ASX: 6/7/23); 3. ResearchDx EXO-NET Services Licence (ASX 5/9/23) Promega The Contract Diagnostics Organization#19Milestones and catalysts SubB2M and EXO-NET programs moving towards key inflection points For personal use only 19 H2 CY 2023 H1 CY 2024 EXO-NET co-marketing agreement with Promega Results of EXO-OC equivalence study in plasma and serum (n=250) Results SubB2M SPR feasibility study Results SubB2M/CA125 OC analytical validation study Results of SubB2M/CA15-3 BC monitoring study Progress SubB2M partnering TEXO-NET data @ ANZSEV23 meeting Commercial progress SubB2M/CA15-3 LDT Results SubB2M/CA125 OC clinical validation studies NEURO-NET data New EXO-NET collaborations/partnering Progress EXO-OC test collaboration and clinical data INOVIQ#20Summary | Next generation diagnostic solutions advancing towards key milestones For personal use only 20 20 2 3 4 Innovative Company Patented Technology Strong Pipeline Compelling Results Focused on next-gen diagnostic and exosome solutions to improve health outcomes in cancer and other diseases Proprietary SubB2M & NETS technologies with multiple diagnostic and therapeutic applications Deep pipeline for detection of common and/or deadly cancers Data for SubB2M and exosome- based tests demonstrating earlier and more accurate detection for breast & ovarian cancers Commercialized Products Products in-market for exosome isolation and bladder cancer detection 6 7 Partnering for Growth Commercialisation through partnering to deliver solutions to global markets Experienced Leadership Track record in healthcare leadership, exosome science, diagnostic development and commercialisation 8 Funding our Future Cash of $6.3m as at 30 Sep 23 to fund operations and pipeline development INOVIQ#21Contacts For personal use only 21 224 INOVIQ Ltd 23 Normanby Road Notting Hill VIC 3168 Australia P +61 3 9548 7586 E [email protected] W www.inoviq.com Dr Leearne Hinch | CEO E [email protected] M +61 400414416 themocnic DINOVIQ